Regulatory Advances in Biosimilars

An FDA analysis of drug prices from 1999 to 2004 found that the discount from generic competition was just 6 percent with one generic competitor, but jumps to 48 percent with two generic competitors, 56 percent with three, 61 percent with four and 67 percent with five generic producers in a market. Within two years of the expiration of the patent for the popular drug Zantac in mid-1997, generic versions accounted for 90 percent of the treatment’s total sales, and the price for patients was about 10 percent of its pre-generic price. European patents on biologic treatments began to expire in 2000, and in April 2006, Sandoz and Biopartners received EMEA approval for the first European Biogenerics, two products containing human growth hormone.

  • Biosimilars regulation
  • BLA filing for Biosimilars
  • Regulatory prospects of BRIC countries
  • Aparadigm of traditional generics to Biosimilars
  • Biowaiver approval for Biosimilars
  • Generic Biosimilars
  • Regulatory Prospects in BRIC countries

Related Conference of Regulatory Advances in Biosimilars

February 28-March 01, 2019 ANA Crowne Plaza |

Global Pharmaceutical and Pharma Industry Conference

Osaka, Japan
March 18-19, 2019

13th International Conference on Biosimilars and Biologics

Amsterdam | Netherlands
July 26-27, 2019

13th Asian Biologics and Biosimilars Congress

Mercure Albert Park | Melbourne, Australia

Regulatory Advances in Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in